CIBC Private Wealth Group LLC increased its holdings in Catalent, Inc. (NYSE:CTLT – Get Rating) by 0.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 158,063 shares of the company’s stock after purchasing an additional 359 shares during the period. CIBC Private Wealth Group LLC owned 0.09% of Catalent worth $20,236,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of CTLT. Assetmark Inc. purchased a new position in Catalent in the 3rd quarter worth approximately $34,000. Concord Wealth Partners lifted its holdings in Catalent by 154.3% in the 4th quarter. Concord Wealth Partners now owns 267 shares of the company’s stock worth $34,000 after purchasing an additional 162 shares in the last quarter. Selective Wealth Management Inc. lifted its holdings in Catalent by 50.0% in the 4th quarter. Selective Wealth Management Inc. now owns 300 shares of the company’s stock worth $38,000 after purchasing an additional 100 shares in the last quarter. Ibex Wealth Advisors purchased a new position in Catalent in the 3rd quarter worth approximately $51,000. Finally, Desjardins Global Asset Management Inc. purchased a new position in Catalent in the 4th quarter worth approximately $70,000. 93.81% of the stock is currently owned by institutional investors.
NYSE CTLT opened at $90.56 on Friday. The company has a market cap of $16.22 billion, a P/E ratio of 27.95, a P/E/G ratio of 1.50 and a beta of 1.38. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.19 and a current ratio of 2.85. The business’s 50 day moving average price is $101.51 and its 200-day moving average price is $113.34. Catalent, Inc. has a fifty-two week low of $86.34 and a fifty-two week high of $142.64.
A number of research analysts recently commented on CTLT shares. Zacks Investment Research raised Catalent from a “hold” rating to a “strong-buy” rating and set a $143.00 price target on the stock in a report on Tuesday, January 4th. Morgan Stanley reduced their price objective on Catalent from $160.00 to $145.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 2nd. Barclays reduced their price objective on Catalent from $160.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, January 27th. Deutsche Bank Aktiengesellschaft reduced their price objective on Catalent from $129.00 to $110.00 and set a “hold” rating on the stock in a research note on Tuesday, April 12th. Finally, StockNews.com began coverage on Catalent in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $142.88.
In related news, CAO Ricky Hopson sold 2,325 shares of the company’s stock in a transaction dated Monday, January 31st. The stock was sold at an average price of $103.39, for a total transaction of $240,381.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Peter Zippelius sold 487,092 shares of the company’s stock in a transaction dated Sunday, February 6th. The shares were sold at an average price of $102.65, for a total value of $49,999,993.80. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.
About Catalent (Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.